Tags : Treat Acute Hepatic Porphyria

Alnylam Reports Results of Givosiran in P-III ENVISION Study to

Tuba Khan April 15, 2019

Shots: The P-III ENVISION study involves assessing of Givosiran vs PBO in patients with acute hepatic porphyria (AHP) ENVISION study results:74% mean reduction of annualized rate of porphyria attacks; 90% […]readmore

Tags : Treat Acute Hepatic Porphyria

Alnylam Reports Results of Givosiran in P-III ENVISION Study to

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Treat Acute Hepatic Porphyria

﻿Alnylam Reports Results of Givosiran in P-III ENVISION Study to

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Alnylam Reports Results of Givosiran in P-III ENVISION Study to